Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company. Cayman Islands-based Legacy Pharma is run by Mark Thompson, the former CEO of ...